{
    "nct_id": "NCT04314895",
    "official_title": "Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of NanoPac® With Standard of Care Therapy in Subjects With Lung Cancer",
    "inclusion_criteria": "* Signed informed consent;\n* Age ≥18 years and able to tolerate the EBUS-TBNI procedure;\n* Histologically/cytologically confirmed lung cancer. Eligible subjects may include, for example: primary or recurrent non-resectable disease, locally advanced stages II and III with nodal disease, stage IV advanced disease;\n* At least one lesion documented via imaging (within 4 weeks of Screening) which can be accessed using EBUS-TBNI;\n* Subject is not a candidate for surgery;\n* Has received or plans to receive SOC chemotherapy; adequate hematologic recovery must be confirmed according to the institution's SOC;\n* Performance Status (ECOG) 0-2 at study entry;\n* Life expectancy of at least 6 months;\n* Adequate marrow, liver, and renal function at study entry;\n\n  * ANC ≥ 1.5 x 109/L;\n  * Hemoglobin ≥ 9.0 grams/dL;\n  * Platelets ≥ 75 x 109/L;\n  * Total bilirubin ≤ 1.5x institutional ULN;\n  * AST/ ALT ≤ 2.5x institutional ULN;\n  * Creatinine ≤ 1.5x institutional ULN;\n* Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.*\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Significant cardiac disease (Class III or IV per New York Heart Association guidelines);\n* Active bacterial, viral, or fungal infections (including active AIDS, hepatitis B or hepatitis C);\n* Symptomatic central nervous system (CNS) metastasis which are neurologically unstable, or CNS disease requiring increase in steroid dose (treated metastatic disease and stable steroid use are not excluded)\n* Known hypersensitivity to study agent;\n* Pregnant or breastfeeding women.",
    "miscellaneous_criteria": ""
}